Skip to main content
. 2022 Sep 22;28(11):2309–2320. doi: 10.1038/s41591-022-01980-3

Extended Data Fig. 3. External validation in four independent cohorts.

Extended Data Fig. 3

a) Displayed are discriminative performances described by the C-index for UK Biobank and the four external validation cohorts, Whitehall II (WHII), Rotterdam Study (RS), Leiden Longevity Study (LLS), and the PROSPER trial (PROSPER). CPH models were trained on the metabolomic state model (MET) as fitted on UK Biobank and applied to each cohort, as well as on Age+Sex and Age+Sex+MET. The metabolomic state is predictive in the replication cohorts for all assessed endpoints. Dots indicate the median performance, while whiskers indicate the 95% confidence interval (CI) determined by bootstrapping over 1000 iterations. b) Age+Sex adjusted hazard ratios (HRs) for the metabolomic state in all five cohorts. A unit standard deviation increase in the metabolomic state corresponds to an HR increase in predicted risk. Statistical measures were derived from n = 6.117 (Whitehall II), n = 2949 (Rotterdam Study), n = 1655 (Leiden Longevity Study), and n = 960 (PROSPER) individuals as indicated. Data are presented as median (center of error bar) and 95% CI (line of error bar) determined by bootstrapping over 1000 iterations.